ADCT
NYSEADC Therapeutics SA
Price$1.03-2.39 (-69.88%)
2026-05-212026-08-25
News · 26 weeks48+100%
2026-03-012026-08-23
Mix2790d
- Insider11(41%)
- SEC Filings7(26%)
- Other4(15%)
- Earnings3(11%)
- Analyst2(7%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by ADC Therapeutics SASCHEDULE 13G - ADC Therapeutics SA (0001771910) (Subject)
- SECSEC Form S-8 filed by ADC Therapeutics SAS-8 - ADC Therapeutics SA (0001771910) (Filer)
- SECSEC Form 10-Q filed by ADC Therapeutics SA10-Q - ADC Therapeutics SA (0001771910) (Filer)
- SECADC Therapeutics SA filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ADC Therapeutics SA (0001771910) (Filer)
- PRADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational UpdatesSecond quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASHCompany evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meetingCompany to host conference call today at 8:30 a.m. EDTLAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational updates. ZYNLONTA® commercial performance as a monot
- PRADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026LAUSANNE, Switzerland, Aug. 6, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, August 13, 2026, at 8:30 a.m. EDT to report financial results for the second quarter of 2026 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A li
- INSIDERChief Medical Officer Zaki Mohamed was granted 213,900 shares, increasing direct ownership by 31% to 896,317 units (SEC Form 4)4 - ADC Therapeutics SA (0001771910) (Issuer)
- INSIDERChief Legal Officer Graham Peter J was granted 221,100 shares, increasing direct ownership by 36% to 841,640 units (SEC Form 4)4 - ADC Therapeutics SA (0001771910) (Issuer)
- INSIDERChief Financial Officer Carmona Jose was granted 203,700 shares, increasing direct ownership by 28% to 938,076 units (SEC Form 4)4 - ADC Therapeutics SA (0001771910) (Issuer)
- INSIDERChief Executive Officer Mallik Ameet was granted 675,000 shares, increasing direct ownership by 47% to 2,121,769 units (SEC Form 4)4 - ADC Therapeutics SA (0001771910) (Issuer)
- SECADC Therapeutics SA filed SEC Form 8-K: Leadership Update8-K - ADC Therapeutics SA (0001771910) (Filer)
- PRADC Therapeutics Announces New Employee Inducement GrantLAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on July 1, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment. The Grant was approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and con
- PRADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamabFull data expected in fourth quarter of 2026LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (r/r DLBCL).
- SECADC Therapeutics SA filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ADC Therapeutics SA (0001771910) (Filer)
- PRADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory PrioritiesPlanned ~17% workforce reduction expected to generate annualized estimated savings of approximately $10M, enhancing financial flexibility Company focused on delivering upcoming regulatory and clinical milestones, including planned LOTIS-5 sBLA submission and full LOTIS-7 data by end of 2026LAUSANNE, Switzerland, June 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced a strategic reorganization to focus resources behind key value-driving initiatives in support of the ZYNLONTA® (loncastuximab tesirine-lpyl) franchise.
- ANALYSTADC Therapeutics downgraded by H.C. WainwrightH.C. Wainwright downgraded ADC Therapeutics from Buy to Neutral
- ANALYSTADC Therapeutics downgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts downgraded ADC Therapeutics from Outperform to Sector Perform and set a new price target of $2.00
- INSIDERDirector Azelby Robert was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 40% to 112,805 units (SEC Form 4) to cover withholding tax4 - ADC Therapeutics SA (0001771910) (Issuer)
- INSIDERDirector Squarer Ron was granted 45,000 shares and covered exercise/tax liability with 15,196 shares, increasing direct ownership by 32% to 123,431 units (SEC Form 4) to satisfy withholding obligation4 - ADC Therapeutics SA (0001771910) (Issuer)
- INSIDERDirector Sandor Victor was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 30% to 140,686 units (SEC Form 4) (tax withholding)4 - ADC Therapeutics SA (0001771910) (Issuer)
- INSIDERDirector Monges Viviane was granted 45,000 shares and covered exercise/tax liability with 2,596 shares, increasing direct ownership by 29% to 186,447 units (SEC Form 4) to cover withholding tax4 - ADC Therapeutics SA (0001771910) (Issuer)
- INSIDERDirector Hug Peter was granted 45,000 shares and covered exercise/tax liability with 2,156 shares, increasing direct ownership by 19% to 263,344 units (SEC Form 4) to cover withholding tax4 - ADC Therapeutics SA (0001771910) (Issuer)
- INSIDERDirector Bizzari Jean-Pierre was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 30% to 139,302 units (SEC Form 4) to satisfy withholding tax4 - ADC Therapeutics SA (0001771910) (Issuer)
- INSIDERDirector Coughlin Timothy was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 81% to 72,400 units (SEC Form 4) (tax withholding)4 - ADC Therapeutics SA (0001771910) (Issuer)
- SECADC Therapeutics SA filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ADC Therapeutics SA (0001771910) (Filer)
ADCT FAQ
7 questionsWhat does ADC Therapeutics SA do?
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or...Where does ADCT stock trade?
ADC Therapeutics SA (ADCT) is listed on NYSE.What sector and industry is ADCT in?
ADC Therapeutics SA operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did ADC Therapeutics SA go public?
ADC Therapeutics SA (ADCT) completed its IPO in 2020.What are analysts saying about ADCT?
ADC Therapeutics SA has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral on 2026-06-08.What companies are similar to ADCT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ADCT side-by-side with any of them on Quantisnow.How can I track ADCT on Quantisnow?
Quantisnow aggregates ADC Therapeutics SA's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADCT to receive live email and push alerts on every new disclosure.